A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)." Lung cancer is the ...
Dec. 4, 2003 (San Antonio) — Docetaxel (Taxotere) produced better overall survival and longer time to progression than paclitaxel (Taxol) in a randomized head-to-head trial of the two taxanes widely ...
TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Memgen, Inc., a clinical-stage biotechnology company developing oncolytic immunotherapy for solid tumors, today announced the dosing of the first patient ...
Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...
The median overall survival was 19.6 months with pembrolizumab plus docetaxel and 19.0 months with docetaxel alone. The combination of pembrolizumab and docetaxel does not improve outcomes over ...
The primary purpose of the study was to validate whether certain genetic variants confer a high risk of TIPN in Black women -- FCAMR GG (homozygous wild-type) or SBF2 mutations -- given that this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback